规格

价格

库存

数量

1 mg

¥ 198

现货

5 mg

¥ 452

现货

10 mg

¥ 617

现货

25 mg

¥ 1,320

现货

50 mg

¥ 2,190

现货

100 mg

¥ 3,490

现货

200 mg

¥ 4,910

现货

1 mL x 10 mM (in DMSO)

¥ 490

现货

生物活性

产品描述	Puromycin aminonucleoside (NSC 3056) is an aminonucleoside antibiotic and a purine analog of puromycin. It can reversibly inhibit dipeptidyl peptidase and cytosolic alanine aminopeptidase, increase podocyte permeability by regulating ZO-1 in an oxidative stress-dependent manner, induce apoptosis, and promote the secretion of migrasomes. It is commonly used to induce nephrotic syndrome models in research.
体外活性	Puromycin aminonucleoside -induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside causes podocyte apoptosis in a time-dependent manner. The IC50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4. Puromycin aminonucleoside (30 μg/mL) markedly enhances p53 protein levels in podocytes. Puromycin aminonucleoside (250 μM) is toxic to both PMAT-expressing and vector-transfected cells [2][4].
体内活性	Rats given Puromycin aminonucleoside (100 mg/kg, s.c.) gain less weight and their serum creatinine levels are higher than the control rats. The number of podocytes per glomerulus is 95.5±17.6 in the control rats, 90.7 on Day 4 in Puromycin aminonucleoside (8 mg/100 g, i.v.)-treated nephrosis rats. The amount of nephrin per glomerulus in control rats is 1.02±0.11 fmol and those in Puromycin aminonucleoside nephrosis rats are reduced to 0.46±0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte is significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats [5][6].
疾病造模方案	构建嘌呤霉素氨基核苷肾病（PAN）模型造模机制： Puromycin aminonucleoside（PA）通过黄嘌呤氧化酶途径诱导氧化应激，损伤肾小球足细胞；破坏足突间裂孔隔膜（SD）结构，导致关键蛋白 podocin 从裂孔隔膜移位至细胞质（通过网格蛋白介导的内吞途径，与早期内体标志物 Rab5 共定位）；引发足突融合、足细胞脱落及肾小球硬化，最终导致大量蛋白尿，模拟人类微小病变肾病（MCD）和局灶节段性肾小球硬化（FSGS）的核心病理特征。相关产品： Puromycin aminonucleoside (T16684) 造模方法：实验对象：大鼠, Sprague-Dawley（SD）, 雄性, 体重约 200 g 给药剂量和方式： 15 mg/100 g 体重, 腹腔注射（i.p.）给药频率和周期：单剂量模型验证： 1. 功能指标：24 小时尿蛋白显著升高（给药后 4 天开始升高，14 天达峰值，p<0.001），尿白蛋白排泄增加；血清肌酐、尿素氮轻度升高； 2. 分子指标：免疫荧光检测显示podocin 与 synaptopodin 染色间隙（podocin gap）显著扩大（7-14 天 p<0.05），podocin 细胞质定位比例升高；免疫电镜可见 podocin 在足细胞胞质内呈囊泡状分布（金颗粒计数增加，p<0.05）； 3. 病理指标：光镜下肾小球结构紊乱，足突融合、局灶性硬化；电镜下裂孔隔膜破坏，足突广泛融合，肾小球基底膜（GBM）与足细胞连接疏松； 4. 特异性验证：podocin 移位仅发生于严重足细胞损伤，微小病变肾病（MCD）样本中无 podocin gap，可区分模型特异性损伤。注意事项：每组在 PA 注射后 0、4、7、14 和 28 天时处死三只大鼠。在大鼠被戊巴比妥钠麻醉（100 mg/kg;日本大阪大日本住友制药），他们通过腹主动脉灌注，使用 PLP 固定缓冲剂（4%对甲醛，0.1 百万赖氨酸）。参考文献：Fukuda H,et,al. Podocin is translocated to cytoplasm in puromycin aminonucleoside nephrosis rats and in poor-prognosis patients with IgA nephropathy. Cell Tissue Res. 2015 May;360(2):391-400.
别名	氨基核苷嘌呤霉素, NSC 3056

化学信息

分子量	294.31
分子式	C₁₂H₁₈N₆O₃
CAS No.	58-60-6
Smiles	CN(C)c1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](N)[C@H]1O
密度	1.7 g/cm3

储存&溶解度

存储

溶解度信息

H2O: 50 mg/mL (169.89 mM), Sonication is recommended.

DMSO: 33 mg/mL (112.13 mM), Sonication is recommended.

体内实验配方

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.8 mM), Sonication is recommended.

请按顺序添加溶剂，在添加下一种溶剂之前，尽可能使溶液澄清。如有必要，可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考，体内配方并不是绝对的，请根据不同情况进行调整。

溶液配制表

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	3.3978 mL	16.9889 mL	33.9778 mL	169.8889 mL
5 mM	0.6796 mL	3.3978 mL	6.7956 mL	33.9778 mL
10 mM	0.3398 mL	1.6989 mL	3.3978 mL	16.9889 mL
20 mM	0.1699 mL	0.8494 mL	1.6989 mL	8.4944 mL
50 mM	0.0680 mL	0.3398 mL	0.6796 mL	3.3978 mL
100 mM	0.0340 mL	0.1699 mL	0.3398 mL	1.6989 mL

Puromycin aminonucleoside

Puromycin aminonucleoside

产品介绍

计算器

体内实验配液计算器

剂量转换

引用文献

关键词

Puromycin aminonucleoside

Puromycin aminonucleoside